NEKTAR Therapeutics
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
Volunteers needed for up to a 59 week long clinical trial with up to 19 office visits for an investigational product. $1,200.00 stipend available. Additional compensation will be available for participants who are travelling extensive distance to participate (with prior approval).
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 18+ years of age (max age of 70 years)
2.) Have MODERATE to SEVERE eczema (atopic dermatitis)
3.) Minimum of 10% eczema affected body surface area to be determined by Investigator at Screening Visit.
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) Prior use of biological medications or JAK inhibitors for treatment of Atopic Dermatitis
2.) Unwilling to discontinue current atopic dermatitis treatments
3.) Female who is pregnant or breastfeeding
ClinicalTrials.gov Identifier: NCT NCT06136741
https://clinicaltrials.gov/study/NCT06136741?term=nektar&rank=6
Nektar Therapeutics Logo
We love our patients, so feel free to visit during normal business hours.
510 S Cowley Spokane, WA 99202
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
Copyright © 2024 Principle Research Solutions,llc - All Rights Reserved.
Your One-Stop Research SOLUTION
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.